Volume | 30,100 |
|
|||||
News | - | ||||||
Day High | 0.7027 | Low High |
|||||
Day Low | 0.66 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Cardio Diagnostics Holdings Inc | CDIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.70 | 0.66 | 0.7027 | 0.70 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
178 | 30,100 | US$ 0.6947334 | US$ 20,911 | - | 0.171 - 3.56 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
10:12:16 | 2 | US$ 0.698 | USD |
Cardio Diagnostics Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
13.54M | 20.52M | - | 17k | -8.38M | -0.41 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cardio Diagnostics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CDIO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.80 | 0.82 | 0.65 | 0.7128723 | 334,380 | -0.1389 | -17.36% |
1 Month | 1.29 | 1.3446 | 0.65 | 0.947015 | 361,603 | -0.6289 | -48.75% |
3 Months | 2.02 | 2.05 | 0.65 | 1.40 | 402,267 | -1.36 | -67.27% |
6 Months | 0.2022 | 3.56 | 0.1976 | 1.37 | 7,417,992 | 0.4589 | 226.95% |
1 Year | 2.31 | 3.56 | 0.171 | 1.32 | 3,942,196 | -1.65 | -71.38% |
3 Years | 4.25 | 8.4999 | 0.171 | 2.05 | 3,286,602 | -3.59 | -84.44% |
5 Years | 4.25 | 8.4999 | 0.171 | 2.05 | 3,286,602 | -3.59 | -84.44% |
Cardio Diagnostics Description
Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease. |